What’s Trending in the News – April 2025

Stay ahead of the latest BioPharma trends and industry insights

Pharma U.S. Manufacturing Moment: Where Companies are Making the Biggest Moves

US Manufacturing
Via Getty Images

Source: PharmaVoice

The tariff war has prompted new calls to reshore manufacturing. Several large organizations have already made the leap as BioPharma leverages technological advances such as continuous manufacturing, AI-enabled processes, robotics and automation have brought labor costs down, and regulators are offering more support.

READ FULL ARTICLE

U.S. FDA to Phase Out Animal Testing in Drug Development

FDA

Source: Reuters

The U.S. FDA plans to replace animal testing in the development of monoclonal antibody therapies and other drugs with “human-relevant methods,” including the use of AI-based models. The new approach would help improve drug safety, as well as lower R&D costs and drug prices.

READ FULL ARTICLE

Rewriting the R&D Playbook to Account for Shifts in the Investment Landscape

R&D Playbook
Via Getty Images

Source: PharmaVoice

A recent Deloitte report highlights the significant shift in Big Pharma’s R&D investment strategies with industry returns rising to 5.9% for the top 20 BioPharma companies.

READ FULL ARTICLE

Have questions or need guidance on your peer-to-peer strategy? V2V is here to help!

Recent Posts

Man in suit holding back dominos

Will Your Launch Strategy Succeed or Fail?

The Challenge: A Faster, More Complex Launch Environment In today’s pharmaceutical market, strong science is the foundation, but it doesn’t always guarantee a successful launch....

Read More
Story 2

Industry Insights – June 2026

From evolving China deal dynamics and prolonged job searches to the growing push for AI-driven drug repurposing, explore how shifts in BioPharma are redefining innovation,...

Read More
FDA Commissioner Marty Makary, M.D.

Industry Insights – May 2026

Biosimilars are gaining U.S. momentum even as patent thickets keep triggering legal fights, small biotechs are feeling the pressure of the FDA’s faster-moving approval environment,...

Read More